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Sary To establish whether p53 mutation precedes or follows clonal divergence in human colorectal
carcinomas, 17 tumours were analysed at multiple sites (2-5 each) for single-strand conformation polymor-
phisms (SSCP) within exons 5-8 of the p53 gene. A previous study had demonstrated subclones of differing
DNA pkoidy in these tumours, but all showed immunocytochemical evidence for p53 stabilisation, using the
monockal antibody PAb 1801. Mutations within exons 5-8 of p53 were identified by the presence of an
abnormally migrating band in 10 of the 17 carcinomas: five in exon 5, four in exon 7 and one in exon 8. In
each of these positive cases samples from different parts of the cacino showed identiclW gd migration
patterns in SSCP analysis. Similarly, the rm_ainin seven tumours were concordant for absence of band shift
across all samples of each tumour. Six SSCP-positive cases contained multiple populations differing in DNA
ploidy, while four were homogeneously diploid or aneuploid throughout. Very similar proportions were
observed in the SSCP-negtive cases. In four positive tumours the mutation was confirmed by sequencing or
through alteration of nucleotide-specific restriction enzyme cleavage. Identical mutations appeared in every
sample from the same tumour. The results provide unequivocal evidnce that the same mutant allele of p53 is
present throughout each tumour bearing a mutation, regardless of the clonal variation identified by analysis of
DNA ploidy. We conclude that in colorectal tumorigenesis mutation of p53 occurs as a single event which
precedes and may facilitate the aneuploid clonal divergence of carcinomas.
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Inactivation of the tumour-suppressor gene p53 is an impor-
tant step in the development of the majority of human
cancers (Hollstein et al., 1991). Functional inactivation
occurs most commonly as a result of missense mutation
(Baker et al., 1989) but can also result from interaction with
oncogenic viral or cellular proteins (Mietz et al., 1992;
Momand et al., 1992). The p53 protein is a sequence-specific
DNA-binding protein that is active as a transcription factor
(Bargonetti et al., 1991) and can interact directly with the
replication apparatus (Dutta et al., 1993). There is good
evidence that its normal function is to establish GI check-
point control in response to DNA damage, so allowing time
for DNA repair (Kastan et al., 1991) or the initiation of
apoptosis (Clarke et al., 1993). Lack of functional p53 pro-
motes genomic instability (Bischoff et al., 1990; Harvey et al.,
1993), which is probably a key factor in acquisition of the
multiple 'hits' required for carcinogenesis (Nowell, 1976).
We have recently shown that human colorectal carcinomas
containing immunohistochemically detectable p53 are more
likely to contain multiple aneuploid DNA stem lines than
those which are p53 negative (Carder et al., 1993). This result
is in keeping with a relationship between p53 and genomic
instability. We also reported that in carcinomas containing
stabilised p53 the abnormality was almost always present
throughout the tumour even though DNA analysis revealed
the presence of divergent stem lines. From these findings we
concluded that p53 stabilisation is a critical early event in
cancer evolution favouring the development oftetraploid and
other aneuploid sublines. Since it is now clear that p53
stabilisation can be the result ofthe tumour cell environment,
independent of mutation (Vojtsek and Lane, 1993), we felt it
was important to re-examine these cases for more definitive
evidence, firstly, that mutation of p53 had occurred and,
secondly, that it preceded clonal divergence in tumour pro-
gression. To this end we used the technique of single-
stranded conformation polymorphism (SSCP) analysis (Orita
et al., 1989; Glavac and Dean, 1993) to identify mutant
alleles of p53 and confirm that the same mutant allele was
present in all of the samples taken from any one carcinoma,
despite independent evidence of clonal divergence between
these samples.
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Materials and methods
Samples
Sixty-four samples from 17 colorectal carcinomas from our
previously published series (Carder et al., 1993) were studied.
An average of four samples per tumour (range 2-5) were
analysed and compared with normal colonic mucosa from
the same individual. All samples of all tumours contained
stabilised p53 as determined by immunohistocity using
PAb 1801 (Oncogene Science). Flow cytometry was per-
formed on frozen tissue and immunohistochemistry was per-
formed on tissue fixed in periodate lysine paraformaldehyde
(PLPD), both as described previously. To minimise possible
confusion between tumour and non-neoplastic stroma,
samples were assessed as diploid only if tumour cels
occupied in excess of 50% of tissue sections from which the
corresponding flow cytometric analysis showed a diploid
main peak. Samples were considered aneuploid if a separate
peak, distinct from the diploid peak, was identified, and
aneuploid populations from different samples of the same
tumour were considered identical unlss they differed in
DNA index by more than 0.1. Samples were considred
tetraploid if a separate peak with DNA index between 1.9
and 2.1 comprised more than 10% of the nuclei.
Single-strand conformation polymorphism (PCR-SSCP)
analysis
The polymerase chain reaction (PCR) was performed on
0.1- I Ijg of genomic DNA samples, in an 100 al reaction
containing 200gM of each deoxynucleotide, 50pmol of each
primer and 2 units of a thermostable Taq polymerase in the
relevant buffer. PCR was performed in a DNA thermocycler
(Hybaid) with the following temperature profile: one cycle of
94'C for 5 min. 30 cycles of 94'C for I min, 58-C for 1 min,
72'C for 1 min, and one cycle of 72 C for 10 min. The
primers were as follows (5' to 3'): exon 5 up TTCCTCTTC-
CTACAGTAGTC and 5 reverse CGATGGTGAGCAGC-
TGGG; exon 6 up CCTCACTGATTGCTCITAGG and 6
reverse CTGAGGTCTGGTTrTGCAACT; exon 7 up
TGTGTTATCTCCTAGGTTGG and 7 reverse GTCAG-
GAGCCACTTGCCA; exon 8 up TCCTATCCTGAGTAG-
TGGT and 8 reverse CGAGGTAAGCAAGCAGGA. Thep53 mutation in colorectal carcinoma by SSCP
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samples were extracted once with 24:1 chloroform/
isoamylalcohol to remove any mineral oil and 5-10gIl was
then denatured in 80 giM sodium hydroxide, 10 liM EDTA, at
48°C for 5 min. Two microlitres sequencing stop solution was
added, and the whole sample loaded onto a 5% glycerol,
0.5 x MDE Hydrolink gel (Hoefer Scientific). The gel was
run in 1 x TBE on the SE400 PAGE apparatus (Hoefer
Scientific) at 25°C, 20 W, for 2-3 h.
Normal and tumour samples from the same individual
were run together for comparison. Tumour samples were
classified as SSCP positive if a discrete additional band was
observed. Bands were visualised by a silver stain (BioRad) as
per the manufacturer's instructions with additional washes.
The gel was dried on to 3MM paper and laminated.
Sequence analysis
A total of nine samples from two cases with band shift on
SSCP throughout were sequenced by the dideoxy chain-
termination technique as described previously (Cripps et al.,
1994) using a commercial kit (Sequenase, Amersham).
Restriction enzyme digestion using MspI
A total of eight samples from two cases with band shift on
SSCP throughout and known to contain a CGG-*CAG
mutation in codon 248 were analysed by restriction enzyme
digestion using MspI. As described previously (Cripps et al.,
1994), disruption of the CCGG recognition site by mutation
results in loss of the 135 bp and 168 bp bands and creates an
additional 303 bp band.
Results
Seventeen carcinomas which had been sampled at multiple
sites and demonstrated immunmohistochemical positivity for
PAb 1801, and for which DNA ploidy values were available,
were studied. In 14 cases the majority of nuclei stained
intensely. Three cases showed the 'mosaic' pattern, in which
positive nuclei were scattered sparsely throughout the
tumour. Twelve cases contained multiple clonally distinct
subpopulations as determined by assessment of DNA ploidy
by flow cytometry, with eight containing two and four con-
taining three variant subpopulations.
From each tumour sample exons 5-8 of the p53 gene were
amplified individually and analysed by SSCP. Band shifts
indicating the presence of a mutant p53 allele with altered
conformation were detected by SSCP in 10 of the 17 car-
cinomas (59%). An average of four samples per tumour were
studied, and the same band shift was present in all samples
of each SSCP-positive case, suggesting a single clonal muta-
tion event (Figure 1). The presence of a mutation in the
amplified p53 fragment revealing the band shift was con-
firmed in nine samples of two cases by direct nucleotide
sequence analysis. Six samples from one case contained a
CGC-*CAC mutation in codon 175 and three samples from
the other case contained a CAT-*TAT mutation in codon
179 (Figure 2). In two further cases a mutation in codon 248
was confirmed in a total of eight samples using the MspI
restriction enzyme digestion technique (Figure 3). In all, five
mutations occurred in exon 5, four in exon 7 and one in exon
8. Six cases with SSCP-confirmed mutations contained multi-
ple divergent populations as detected by assessment of DNA
ploidy, indicating clonal evolution subsequent to mutation
(Figure 4). All samples of the SSCP-negative cases were
concordant for absence of band shift, confirming that muta-
tion had not occurred (at any rate in this commonly affected
part of the p53 gene) during carcinoma progression in these
cases. All cases with mutation demonstrated strong positive
staining for PAb 1801 in a majority of tumour cell nuclei,
but four cases with similarly strong staining were SSCP
negative in exons 5-8. The relationship between
immunocytochemistry and mutation is described more fully
elsewhere (Cripps et al., 1994), in a larger number of cases
including the present 17.
Figure 1 Identical band shifts are revealed by SSCP analysis in
all divergent subpopulations of a colorectal carcinoma. N, nor-
mal tissue; TI -3, multiple samples from the same carcinoma
(DNA index: TI, 1.5/1.6; T2, 1.5; T3, 1.6).
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Dideoxynucleotide sequencing conforms a CAT-*TAT
in codon 179 (exon 5) in all three samples from this
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Figure 3 Mspl restriction digestion of exons 7-9 confirms a
mutation in codon 248 in all tumour samples. Loss of the CCGG
recognition site creates an additional 303 bp band and results in
loss of the smaller 135 bp and 168 bp bands. The smaller bands
are due to contaminating normal tissue.
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Figue 4 Relationship between p53 mutation and clonal evolu-
tion. Over all sampled stem lines from any one tumour, band
shifts on SSCP analysis of exons 5-8 were either uniformly
present (closed symbols) or uniformly absent (open symbols). o.
diploid; 0. tetraploid; other symbols aneuploid with different
aneuploid stem lines within the same tumour being designated by
different stem lines. D. diploid; T. tetraploid: A, and A. aneu-
ploid-
Disczss
We have used the technique of single-stranded conformation
polymorphism (SSCP) analysis to detect clonality of p53
mutation in colorectal carcinomas. SSCP provided a sensitive
method of detecting mutations, as mutant alleles generate
characteristic band shifts on electrophoresis under non-
denaturing conditions (Orita et al.. 1989). The technique is
sufficiently powerful to allow distinction between sequences
differing in a single base pair (Cripps et al., 1994). While in
theory one might expect a mutant allele to create at least two
additional conformers (one from each strand). often only one
is observed, and it appears that most new conformers derive
from the punrne-nrch strand (Glavac and Dean. 1993).
Using SSCP we have demonstrated identical band shifts in
the same exon in subclones of carcinomas that diverge in
DNA ploidy. and also in carcinomas which are homogene-
ously diploid or aneuploid. We interpret this to indicate that
p53 mutation occurs prior to divergence of clones differing in
DNA ploidy. and hence any one tumour possesses a single
p53 mutation throughout. In a large series of carcinomas
reported separately (Cnrpps et al.. 1994) we have confirmed
by sequencing that band shifts detected by SSCP invariably
denote mutation, and that the technique used here identifies
more than 70% of all naturally occurring mutations in the
region of p53 studied (exons 5-8). It may be argued that
identical band shifts might still represent different point
mutations within the same amplified fragment. We feel that
this interpretation is unlikely for three reasons. Firstly. even
minor differences in nucleotide substitution (e.g. in adjacent
positions of the same codon) can lead to profound differences
in band shift by SSCP analysis using the methods employed
here (Cripps et al.. 1994). Secondly. in the now considerable
literature on p53 mutations in cancer, the occurrence of two
distinct mutations in the same exon in any one tumour is
uncommon. Finally, we have used direct sequencing to
confirm identity of mutation throughout in two cases. and in
a further two we have used a rapid restriction enzyme diges-
tion technique to confirm identity of mutation site.
The observation that an identical mutation in p53 occurs
throughout affected carcinomas, including those with and
without clonal divergence in DNA ploidy. provides strong
evidence for a single mutational event early in the develop-
ment of these cancers. Around '0-300o of all colorectal
carcinomas containing immunohistochemically stable p53
appear not to contain p53 mutations (Wynford-Thomas.
1993; Baas et al., 1994: Cripps et al.. 1994) but examples of
these in this series also showed divergent subclones concor-
dant in p53 immunocytochemistry. Hence, even the non-
mutational abnormalities that affect p53 stability may also be
an early event. The data presented here emphasise the central
role of wild-type p53 in preventing one type of genomic
instability. This instability appears to result from continued
DNA replication in the presence of DNA damage (Lane,
1992; Livingstone et al.. 1992: Yin et al., 1993) and tends to
produce near-tetraploid subclones (Carder et al.. 1993). It is
interesting that the selective growth advantage afforded by
this instability appears to be a feature favouring carcinoma
rather than adenoma growth. since p53 mutations are
unusual in adenomas. Other lesions involved in colorectal
tumorigenesis but unrelated to p53. such as mutation in the
DNA repair genes implicated in hereditary non-polyposis
colon cancer (Peltomaki et al., 1993), also initiate genomic
instability, albeit of a different type, and associate preferen-
tially with carcinoma rather than adenoma.
In conclusion we establish here by DNA analysis the im-
pression gained from our previous immunohistochemical
study: in colorectal tumorigenesis p53 mutation is a critical
early lesion occurring as a single clonal mutational event
which precedes and probably facilitates the emergence of
divergent aneuploid tumour subpopulations.
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